Buyout buzz: Allergan made a pass at Shire before Valeant came calling

Damian Garde Before it started getting unwanted attention from the takeout artists at Valeant, Allergan made buyout overtures of its own to Shire, Reuters reports, getting little interest ...

Pfizer, Novartis and 3 others put an extra $1M each into Q1 lobbying

Eric Palmer Big Pharma companies, like other corporate beings, spend millions on lobbying in Washington, DC. In fact, a handful of companies spent $ 1 million more each in the first ...

Ignoring harsh lessons, Pfizer prepares to pounce on AstraZeneca

John Carroll The Financial Times reported Sunday evening that Pfizer may make a public declaration of its interest in buying out AstraZeneca within days after renewing an overture that ...

AbbVie’s Humira turns in 18% surge in sales

Eric Palmer AbbVie's Humira is the gift that just keeps on giving, and it presented the still-young drugmaker with a very big boost in the first quarter, powering its sales and ...

Radius dials up a $92M IPO pitch despite tepid market for biotechs

Damian Garde Radius Health is betting the promise of its bone-boosting drug will sway investors to buy into its planned $ 92 million IPO, forging ahead in what has become a shaky market ...

AstraZeneca shareholders pitch a fit about pay

Eric Palmer AstraZeneca CEO Pascal Soriot saw his pay fall last year along with the company's fortunes but that didn't keep large blocks of shareholders from displaying their ...

Actavis global R&D president departs to helm Impax Labs

Alok Saboo FierceBiotech News

Reuters: Allergan broached deal with Shire before Valeant’s hostile bid

Carly Helfand Allergan may have to buy a foreign company and complete a tax inversion if it wants to dodge a hostile takeover bid by Valeant Pharmaceuticals. But a recent attempt to ...

Novartis hopes new COPD study data will draw patients from Glaxo’s Advair

Carly Helfand Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of ...

Isarna snags another $7.6M to advance its cancer immunotherapy

Damian Garde After shifting its focus from antisense therapies to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $ 7.6 million to jump-start the development ...

Biogen brings Quintiles to the R&D table in 5-year pact

Damian Garde Biogen Idec has struck up a far-reaching agreement with CRO giant Quintiles, tapping the contractor to help design, plan and run its Phase II-IV studies. FierceBiotech ...

Bloomberg: Sun plant banned by FDA had same issues faced by Ranbaxy

Eric Palmer Sun Pharmaceutical's $ 3.2 billion buyout offer for Ranbaxy Laboratories also came with a pledge to clean up the act of India's largest generic drugmaker, which ...
Page 2 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS